Imagine where our natural and cheaper version could

New Post Public Reply Private Reply Replies (1) Message Board
zombywolf
1,163
Imagine where our natural and cheaper version could go.

This cancer drug could ascend to the No. 2 spot in 2017

With some of the top-selling drugs potentially seeing their sales decline in the quarters and years that lie ahead, it looks as if Celgene's (NASDAQ:CELG) multiple myeloma blockbuster Revlimid has an outside chance of claiming the No. 2 spot among best-selling therapies in 2017. Celgene stuck by a forecast for $8 billon to $8.3 billion in full-year Revlimid sales, although it's been notoriously conservative with its sales estimates throughout the years.
A doctor discussing diagnostic test findings with an elderly patient.

Image source: Getty Images.

Revlimid's success has been based on a confluence of factors. To begin with, demand for Revlimid is on the rise. An increase in multiple myeloma diagnoses, which is a result of an increase in population and earlier detection of the disease, has lifted demand for a go-to drug used as a first- and second-line therapy.

Celgene also has exceptional pricing power with its lead drug. Though list prices of cancer drugs are often a well-kept secret, Celgene has had little trouble passing along higher price points to insurers and patients. Considering its exceptional market share in treating multiple myeloma, Revlimid shouldn't face much in the way of pricing pressure short of federal legislation that caps drug prices (which is unlikely).

Celgene also notes that duration-of-use for its key therapy has helped its sales growth. Improvements in the multiple myeloma treatment process have allowed patients to remain on Revlimid for a longer period of time, ultimately boosting sales for Celgene.

Lastly, Revlimid has multiple label expansion opportunities beyond multiple myeloma. These include first-line follicular lymphoma, relapsed/refractory indolent lymphoma, and first-line ABC-subtype diffuse large B-cell lymphoma. These aren't major money indications for Celgene like multiple myeloma, but they provide a channel to nicely increase sales.
This is what sets Revlimid apart from the rest of its peers

However, there's an additional factor that sets Revlimid apart from the group. In Dec. 2015, Celgene worked out a settlement with a number of generic-drug manufacturers over Revlimid. One manufacturer will be allowed to introduce a limited generic supply of the drug beginning in March 2022 and extending through 2025. By Jan. 31, 2026, a flood of generic Revlimid can finally enter the market. In effect, Celgene cleared a decade-long runway for its lead drug to keep growing.

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating NeuroOne's Q2 Financial Insights and Growth Strategies

Updated Category News Views 124

NeuroOne Prepares to Release Second Quarter Fiscal Financial Results EDEN PRAIRIE, Minn. — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is set to unveil its financial performance for the fiscal second quarter. The reporting period ended on March 31, and the results will be publicized before market activities commence on May 13. This is an exciting time for...

Continue Reading
FNB's Grand Plan for Ultra-Rich Wealth Clients

Updated Category News Views 79

FNB Corporation's New Strategy Sparks Interest Ah, the ever-competitive world of financial services targets the well-heeled once again. FNB Corporation (NYSE: FNB), headquartered in Pittsburgh, is rolling up its sleeves to offer something new for ultra-high-net-worth clientele. Outside Wall Street's dizzying chaos, this quiet yet aggressive move seems to signal they're up...

Continue Reading
Brazil Stock Market Trends and Key Indicators Update

Updated Category News Views 300

Brazil Stock Market Overview Recently, Brazil's stock market showed signs of decline, particularly on a Thursday when the Bovespa index dropped by 0.79%, reaching a new three-month low. This downturn was primarily driven by losses in critical sectors such as Public Utilities, Electric Power, and Real Estate. Investors and market analysts closely monitor these trends as...

Continue Reading
NEXN Stock Reaches New Heights Amid Positive Market Trends

Updated Category News Views 159

NEXN Stock Hits New Milestone NEXN stock has recently hit a significant milestone, reaching a price of $8.34. This impressive peak is not just a reflection of the company’s strong performance but also highlights a period filled with optimism in the market. With investors closely monitoring the stock's path, this new high may point to a potential sustained upward trend...

Continue Reading
Total Voting Rights Update from PayPoint Plc

Updated Category News Views 108

Understanding PayPoint Plc's Total Voting Rights PayPoint Plc has recently provided an update regarding its voting rights and share capital, which is crucial information for shareholders and those interested in the company. Total Share Capital Information As of August 31, 2024, PayPoint Plc's share capital consists of 72,342,171 ordinary shares, each valued at 1/3 pence....

Continue Reading